Substituted quinazolinones as HCV inhibitors

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9382261
APP PUB NO 20140378485A1
SERIAL NO

14368511

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Inhibitors of HCV replication of formula (I) including stereochemically isomeric forms, salts, and solvates thereof, wherein R and R′ have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HCV inhibitors, in HCV therapy.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • JANSSEN SCIENCES IRELAND UC

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Raboisson, Pierre Jean-Marie Bernard Rosieres, BE 220 1753
Vandyck, Koen Paal-Beringen, BE 60 615

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Jan 5, 2024
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jan 5, 2028
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00